Primary herpes simplex virus (HSV) infection is first infection with either herpes simplex virus-1 (HSV-1) or herpes simplex virus-2 (HSV-2) in individuals who do not have antibodies to either HSV-1 or HSV-2.
First episode-non primary infection is infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-1 or HSV-2 respectively.
Recurrent HSV infection results from reactivation of latent virus. It is usually brought about by triggering factors eg UV light, immunosuppression.
Orolabial HSV disease is mostly caused by HSV-1 that occurs most commonly in children <5 years of age. It is transmitted through close contact with individuals who have active viral shedding.
Genital HSV disease is caused by HSV-2 that is the usual cause of herpes genitalis. It typically occurs in adults and transmitted through sexual contact.
Drake S, Taylor S, Brown D, et al. Improving the care of patients with genital herpes. BMJ. 2000 Sep;321(7261):619-623. PMID: 10977846
Colgan R, Michocki R, Greisman, et al. Antiviral drugs in the immunocompetent host: part I. Treatment of hepatitis, cytomegalovirus, and herpes infections. Am Fam Physician. 2003 Feb;67(4):675, 757-762. PMID: 12613729
Emmert DH. Treatment of common cutaneous herpes simplex virus infection. Am Fam Physician. 2000 Mar;61(6):1697-1706, 1708. PMID: 10750877
Yeung-Yue KA, Brentjens MH, Lee PC, et al. Herpes simplex viruses 1 and 2. Dermatol Clin. 2002 Apr;20(2):249-266. PMID: 12120439
National guideline for the management of genital herpes. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect. 1999 Aug(Suppl 1):S24-S28
Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2006. MMWR Recomm Rep. 2006 Aug;55:1-94. PMID: 16888612
Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008 Jun;168(11):1137-1144. doi: 10.1001/archinte.168.11.1137. PMID: 18541820
Nath AK, Thappa DM. Newer trends in the management of genital herpes. Indian J Dermatol Venerol Leprol. 2009 Dec;75(6):566-574. doi: 10.4103/0378-6323.57716. PMID: 19915235
Opstelten W, Neven AK, Eekhof J. Treatment and prevention of herpes labialis. Can Fam Physician. 2008 Dec;54(12):1683-1687. PMID: 19074705
Ministry of Health Malaysia. National antibiotic guideline 2014, 2nd edition. Pharmaceutical Services Divisions, Ministry of Health Malaysia. http://www.pharmacy.gov.my. Dec 2014. Accessed 16 Jul 2015.
Patel R, Kennedy OJ, Clarke E, et al. 2017 European guidelines for the management of genital herpes. International Union Against Sexually Transmitted Infections (IUSTI). http://www.iusti.org. 2017. Accessed 29 May 2017.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.